BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CT071 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CT071\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06407947-3231@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20270603
DTEND;VALUE=DATE:20270604
SUMMARY:CT071: Phase 1 readout est. (NCT06407947)
DESCRIPTION:CT071\, phase 1\, Multiple Myeloma.\nStudy: Study of CT071 Inje
 ction in High Risk Newly Diagnosed Multiple Myeloma\nEstimated primary com
 pletion: 3 June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ct071#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06407947
URL:https://assetmemo.bio/drug/ct071#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06333509-3231@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20270615
DTEND;VALUE=DATE:20270616
SUMMARY:CT071: Phase 1/2 readout est. (NCT06333509)
DESCRIPTION:CT071\, phase 1/2\, Multiple Myeloma.\nStudy: Anti-GPRC5D CAR-T
  Cells (CT071) in Participants With RRMM or RRpPCL\nEstimated primary comp
 letion: 15 June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ct071#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06333509
URL:https://assetmemo.bio/drug/ct071#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
